Annovis Bio’s (ANVS) Hold Rating Reaffirmed at D. Boral Capital

Annovis Bio (NYSE:ANVS)‘s stock had its “hold” rating restated by stock analysts at D. Boral Capital in a research report issued on Monday,Benzinga reports.

Other equities research analysts have also recently issued research reports about the company. Maxim Group upgraded Annovis Bio from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research note on Friday, October 25th. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Annovis Bio in a research note on Monday, November 11th. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Annovis Bio currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.40.

Annovis Bio Price Performance

NYSE ANVS opened at $2.94 on Monday. The firm’s fifty day moving average price is $4.98 and its 200 day moving average price is $7.18. Annovis Bio has a 12 month low of $2.88 and a 12 month high of $20.00. The company has a market capitalization of $41.87 million, a price-to-earnings ratio of -0.66 and a beta of 1.63.

Annovis Bio (NYSE:ANVS) last posted its earnings results on Friday, November 8th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.33). As a group, sell-side analysts forecast that Annovis Bio will post -2.19 earnings per share for the current year.

Institutional Investors Weigh In On Annovis Bio

Hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. acquired a new position in Annovis Bio during the 3rd quarter worth approximately $31,000. Wilmington Savings Fund Society FSB acquired a new position in Annovis Bio during the third quarter worth about $76,000. Atria Wealth Solutions Inc. purchased a new stake in shares of Annovis Bio during the 4th quarter worth approximately $65,000. Greenwich Wealth Management LLC boosted its position in Annovis Bio by 9.3% during the third quarter. Greenwich Wealth Management LLC now owns 16,475 shares of the company’s stock worth $133,000 after purchasing an additional 1,400 shares in the last quarter. Finally, State Street Corp raised its stake in shares of Annovis Bio by 23.7% during the 3rd quarter. State Street Corp now owns 36,035 shares of the company’s stock worth $290,000 after buying an additional 6,900 shares during the last quarter. 15.83% of the stock is owned by institutional investors and hedge funds.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.